Fund Details
Tata India Pharma & HealthCare Fund Regular Growth
| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 2.64% |
| NAV | ₹14.28 (01 Dec 2020) |
|---|---|
| Fund Started | 28 Dec 2015 |
| Fund Size | ₹354 Cr |
Returns
as per Historical Returns
Comparison
1. Risk is lower compared to the benchmark
2. 1Y Returns are higher than the benchmark
3. 3Y Returns are higher than the benchmark
4. 3Y Returns are higher than the category average returns
1. Asset under management(AUM) is less than 500 Crs. Watch expense ratio when AUM is very low
2. Risk-adjusted returns are lower compared to the category
3. Higher expense ratio
4. Asset under management(AUM) is less than 500 Crs. Watch expense ratio when AUM is very low
5. Risk-adjusted returns are lower compared to the category
6. Higher expense ratio - 2.65%
7. 1Y Returns are lower than the category average returns
Top Holdings
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 13.8% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 9.1% |
| Cipla Ltd. | Healthcare | Equity | 8.7% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 8.2% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 8.2% |
| Narayana Hrudayalaya Ltd. | Healthcare | Equity | 6.0% |
| Lupin Ltd. | Healthcare | Equity | 5.2% |
| Laurus Labs Ltd. | Healthcare | Equity | 5.0% |
| Syngene International Ltd. | Healthcare | Equity | 4.0% |
| Procter & Gamble Health Ltd. | Healthcare | Equity | 3.8% |
Fund Managers
Tata India Pharma & HealthCare Fund Regular Growth Details
Tata India Pharma & HealthCare Fund Regular Growth is a Equity Mutual Fund Scheme launched by Tata Mutual Fund. This scheme was made available to investors on 28 Dec 2015. Rupesh Patel, Sonam Udasi is the Current Fund Manager of Tata India Pharma & HealthCare Fund Regular Growth fund.The fund currently has an Asset Under Management(AUM) of ₹354 Cr and the Latest NAV as of 01 Dec 2020 is ₹14.28.
The Tata India Pharma & HealthCare Fund Regular Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. For units in excess of 12% of the investment,1% will be charged for redemption within 365 Days.
Investment Objective
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Tax Implications
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.
